Infection: 入院时溶血磷脂酰乙醇胺酰基转移酶(LPEAT)水平可以很好地预测社区获得性肺炎严重程度及预后

2021-10-18 MedSci原创 MedSci原创

社区获得性肺炎(CAP)是全球范围内的一种健康问题,有较高的发病率和死亡率。

      社区获得性肺炎(CAP)是全球范围内的一种健康问题,有较高的发病率和死亡率。此外,不同CAP患者的临床的严重程度表现差异很大,轻度的可导致水、电解质酸碱平衡失调,严重的可导致多器官功能障碍甚至感染性休克。由于临床上的多样性表现和缺乏明确的致病病原体,CAP仍然是一个巨大的全球性挑战。以前的研究发现重症肺炎和非重症肺炎患者的溶血磷脂酰乙醇胺 (LPE)浓度为显着下调,而磷脂酰乙醇胺 (PE) 水平显着上调。而溶血磷脂酰乙醇胺酰基转移酶(LPEAT) 是一种酰基转移酶,可将LPE酰化为PE,因此,本研究旨在调查溶血磷脂酰乙醇胺酰基转移酶 (LPEAT) 在CAP中的作用,并评估该酶作为 CAP 疾病严重程度和死亡风险指标的有效性。

 

 

      这项多中心研究于2017年开始实施,共纳入267名CAP患者。在这 267 名患者中,175 名患者是非重度 CAP (non-SCAP),92 名患者患有重度 CAP (SCAP)。此外,研究人员还在研究中招募了15名健康志愿者和42名住院疾病对照者。然后通过定量酶联免疫吸附测定确定 LPEAT 的入院水平。

 

 

      研究结果发现SCAP患者的LPEAT入院水平显着更高,尤其是在非幸存者中这样的现象更加明显,并且不受病因的影响。此外,当根据 PSI 和 CURB-65 评分对患者进行分层时,严重度评分高的患者入院时的 LPEAT 水平高于严重度评分低的患者。LPEAT 在预测 CAP 患者的 SCAP 方面也表现良好。此外,LPEAT可以预测CAP患者的30天死亡率,将LPEAT与临床严重程度评分相结合,进一步提高了死亡率预测的准确性。

 

      本项研究证实升高的LPEAT水平可以可靠地预测入院时CAP患者的疾病严重程度。将 LPEAT 添加到临床评分方法可以提高预后准确性。

 

 

原始出处:

Li Chen. Et al. Admission lysophosphatidylethanolamine acyltransferase level predicts the severity and prognosis of community-acquired pneumonia. Infection (2021).

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2042689, encodeId=c238204268930, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed Mar 02 10:08:02 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729156, encodeId=cf541e291565a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Nov 01 04:08:02 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395911, encodeId=aae913959119f, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Oct 19 10:08:02 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524460, encodeId=0636152446019, content=<a href='/topic/show?id=f0f998396d' target=_blank style='color:#2F92EE;'>#Infection#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9839, encryptionId=f0f998396d, topicName=Infection)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e211601877, createdName=lidong44, createdTime=Tue Oct 19 10:08:02 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2042689, encodeId=c238204268930, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed Mar 02 10:08:02 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729156, encodeId=cf541e291565a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Nov 01 04:08:02 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395911, encodeId=aae913959119f, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Oct 19 10:08:02 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524460, encodeId=0636152446019, content=<a href='/topic/show?id=f0f998396d' target=_blank style='color:#2F92EE;'>#Infection#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9839, encryptionId=f0f998396d, topicName=Infection)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e211601877, createdName=lidong44, createdTime=Tue Oct 19 10:08:02 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2021-11-01 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2042689, encodeId=c238204268930, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed Mar 02 10:08:02 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729156, encodeId=cf541e291565a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Nov 01 04:08:02 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395911, encodeId=aae913959119f, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Oct 19 10:08:02 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524460, encodeId=0636152446019, content=<a href='/topic/show?id=f0f998396d' target=_blank style='color:#2F92EE;'>#Infection#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9839, encryptionId=f0f998396d, topicName=Infection)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e211601877, createdName=lidong44, createdTime=Tue Oct 19 10:08:02 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2042689, encodeId=c238204268930, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Wed Mar 02 10:08:02 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729156, encodeId=cf541e291565a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Nov 01 04:08:02 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395911, encodeId=aae913959119f, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Oct 19 10:08:02 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524460, encodeId=0636152446019, content=<a href='/topic/show?id=f0f998396d' target=_blank style='color:#2F92EE;'>#Infection#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9839, encryptionId=f0f998396d, topicName=Infection)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e211601877, createdName=lidong44, createdTime=Tue Oct 19 10:08:02 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2021-10-19 lidong44

相关资讯

JAHA:HIV感染者社区获得性肺炎与心血管事件风险

调整已知的CVD危险因素和CAP严重程度后,PLWH和未感染HIV的患者在CAP住院期间或之后发生CVD事件的风险相似。然而,在多变量校正模型中,HIV感染与CAP住院后30天死亡率增加相关。

JAMA Pediatr:无需住院的儿童社区获得性肺炎患者,其抗菌疗程可缩短至5天

无需住院的儿童社区获得性肺炎患者,缩短阿莫西林疗程至5天的临床效果与10天疗程相当

Eur Respir J:使用抑酸药的儿童发生社区获得性肺炎风险分析

在使用抑酸药的儿童患社区获得性肺炎的风险增加一倍。长期使用和伴有呼吸系统疾病会增加这种风险,并且在停止治疗后仍然增加。

Lancet:社区获得性肺炎住院患者3天抗生素治疗病情稳定后即可停药

对于β-内酰胺类抗生素治疗3天后病情稳定的社区获得性肺炎住院患者,立即停药人群的预后与8天抗生素治疗人群相当

EClinicalMed:肠道菌群特征与社区获得性肺炎临床预后的相关性

肠道菌群和病毒群特征可能与社区获得性肺炎患者的临床预后有关

CMI:头孢曲松与头孢曲松联合大环内酯类药物治疗HIV/AIDS住院患者社区获得性肺炎的随机对照试验

评价头孢曲松联合大环内酯类药物治疗HIV/AIDS合并社区获得性肺炎(CAP)住院患者与单用头孢曲松治疗相比是否能改善患者预后。